Molecular Imaging of inflammatory joint pathologies of the hand in rheumatoid arthritis patients with Hybrid-PET-SPECT

• Conditions: M05; M06; Seropositive rheumatoid arthritis; Other rheumatoid arthritis

• Registration Number: DRKS00003317
• Lead Sponsor: niversitätsklinikum DüsseldorfInstitut für Diagnostische und Interventionelle Radiologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-11-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

New diagnosed rheumatoid arthritis according to the 2010 ACR/EULAR criteria, disease duration < 6 month, inflammatory involvement of at least one metacarpophalangeal joint or at least one proximal interphalangeal joint

Exclusion Criteria

1) Present malignant disease or history of malignant disease in the last five years (not basal cell carcinoma or squamous cell carcinoma of the skin or in situ carcinoma of the cervix).
2) History of any kind of severe cardiac disease (e.g. decompensated heart insufficency, history of myocardial infarction in the last 12 month, unstable angina pectoris or unregulated hypertension).
3) Severe pulmonary disorder.
4) History of immunodeficiency syndroms (HIV or other) or any rheumatic disease (if not RA) or any demyelinating CNS disease (e.g. MS)
5) History of live vaccination in the past 4 weeks prior to screening. 6) Intraarticular injections in in joints of the surveyed hand (< 4 weeks prior to screening). 7) Any kind of acute or chronic infection (e.g. Hepatitis A,B,C) or predisposition for an infection (e.g. ulcera, diabetes mellitus). 8) Renal disorders (Kreatinin 175 µmol/l, GFR < 30 mg/dl) 9) Zirrhosis or fibrosis of the liver or inadequate liver function. 10) Psychiatric disorders if limting the understanding of participatance in this study 11) Breast feading or Pregnancy. 12) General contradictions against MRI examinations (e.g. implanted cardiac pacemaker/ defibrillator, claustrophobia)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Extent of inflammatory joint changes in hybrid MR-PET and -SPECT on follow-up (6 month under antirheumatic treatment).

Secondary Outcome Measures

Name	Time	Method
Correlation of structural joint pathologies (synovitis, bone marrow edema and erosions) and metabolic joint pathologies seen in PET and SPECT.